Authors:
- Based on rigorous analysis of comprehensive time-series data on the industry
- Written for administrators, policy makers, as well as researchers dealing with regulation and pharma industry
- Presents ways to improve pharmaceutical price controls
Part of the book series: India Studies in Business and Economics (ISBE)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (9 chapters)
-
Front Matter
-
Historical Context and the Motivation for Regulation
-
Front Matter
-
-
The Design of the 2013 DPCO Regulation
-
Front Matter
-
-
The Impact of the 2013 DPCO
-
Front Matter
-
-
Enforcement and Compliance
-
Front Matter
-
-
Back Matter
About this book
This book presents an extensive study on the effectiveness of recent regulations on pharmaceutical prices in India, exploring the weaknesses in the design and implementation of pharmaceutical price controls and investigating what can be done to fix the broken system.
In addition, it examines the extent to which essential medicines are actually made affordable by price controls. The book argues that companies make the pharmaceutical price control regime largely ineffective by coordinating to increase pre-regulation prices; by diversifying horizontally away from the regulated markets and increasing prices in the unregulated markets; by manipulating trade margins; and by refusing to comply with the regulation because the penalties remains negligible.
The book draws on extensive empirical research involving India’s 2013 Drug Price Control Order and widely-used medicines such as paracetamol and metformin to illustrate how firms have weakened regulation. It argues that theregulatory regime can be strengthened by using systematic analysis of product- and region-level data in the Indian pharmaceutical industry, and by screening for the strategies that firms currently employ to circumvent regulation. In closing, it discusses recent efforts to strengthen the implementation of price controls in India and expanding the scope of price controls to medical devices.Authors and Affiliations
-
Erasmus School of Economics, Erasmus University Rotterdam, Rotterdam, The Netherlands
Ajay Bhaskarabhatla
About the author
Ajay Bhaskarabhatla is an associate professor at Erasmus School of Economics, The Netherlands. Ajay’s research on the Indian pharmaceutical industry has been published in top peer-reviewed journals.
Bibliographic Information
Book Title: Regulating Pharmaceutical Prices in India
Book Subtitle: Policy Design, Implementation and Compliance
Authors: Ajay Bhaskarabhatla
Series Title: India Studies in Business and Economics
DOI: https://doi.org/10.1007/978-3-319-93393-1
Publisher: Springer Cham
eBook Packages: Economics and Finance, Economics and Finance (R0)
Copyright Information: Springer International Publishing AG, part of Springer Nature 2018
Hardcover ISBN: 978-3-319-93392-4Published: 09 August 2018
Softcover ISBN: 978-3-030-06652-9Published: 30 January 2019
eBook ISBN: 978-3-319-93393-1Published: 01 August 2018
Series ISSN: 2198-0012
Series E-ISSN: 2198-0020
Edition Number: 1
Number of Pages: IX, 306
Number of Illustrations: 6 b/w illustrations, 18 illustrations in colour
Topics: Health Economics, Emerging Markets/Globalization, Pharmacoeconomics and Health Outcomes, Economic Policy, Development Economics